Fig. 3: Differentially abundant microbial metabolic pathways in participants with mRCC treated with cabozantinib + nivolumab with or without CBM588. | Nature Medicine

Fig. 3: Differentially abundant microbial metabolic pathways in participants with mRCC treated with cabozantinib + nivolumab with or without CBM588.

From: Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Fig. 3

a, Differentially abundant microbial metabolic pathways between baseline and week 13 in participants with the cabozantinib + nivolumab treatment (n = 10). b, Differentially abundant microbial metabolic pathways between baseline and week 13 in participants with the cabozantinib + nivolumab with CBM588 treatment (n = 19). ANCOM-BC was used to perform comparisons between two time points within the same treatment arm (differential features with LFC > 1 and P < 0.05 are indicated). The P value was calculated through a two-sided z-test using the Wilcoxon test statistics. Error bars represent the SE.

Back to article page